| Returns | 1W : 3% , 1M : -5.1%,1Y : 51.9% |
| Peers & Returns | 1W | 1M | 1Y |
| CAPLIN POINT LABORATORIES LTD | 3% | -5.1% | 51.9% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 1.7% | 10.4% | 10.3% |
| DR REDDYS LABORATORIES LTD | 4.9% | -1% | 61.7% |
| DIVIS LABORATORIES LTD | 2.2% | 13.1% | 91.7% |
| CIPLA LTD | -0.3% | -3.5% | 56.4% |
| BIOCON LTD | 1.4% | 4.8% | 51.9% |
| AUROBINDO PHARMA LTD | 4.5% | 12.2% | 88.1% |
| LUPIN LTD | 2.4% | -4.4% | 12.9% |
| TORRENT PHARMACEUTICALS LTD | 0.3% | 2.8% | 37.8% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
17.16
P/E Calculated based on EPS of 28.42
[ Mar2020 - Consolidated Results ] 4.27
P/B Calculated based on Book Value of 114.21
[ Mar2020 - Consolidated Results ] 4.05
P/S Calculated based on Revenues of 910.728 Cr
[ TTM - Consolidated Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-37% -41% -37% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0 0 0 - |
0.04 0 0 0.01 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Consolidated | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
11.68% 14.21% 16.34% 15.18% |
18.01% 14.35% 13.2% 9.71% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
